The Evidence for High-Titer Convalescent Plasma in SARS-CoV-2

Area of Science:

• Infectious Diseases
• Immunology
• Critical Care Medicine

Background:

• Convalescent plasma therapy (CPT) has a history of success in treating respiratory infections.
• Initial observational studies suggested CPT efficacy for SARS-CoV-2, but recent randomized controlled trials (RCTs) show mixed results.
• The timing of CPT administration appears critical, with earlier intervention potentially yielding better outcomes.

Purpose of the Study:

• To evaluate the efficacy of early convalescent plasma therapy for SARS-CoV-2 infection.
• To address the mixed evidence from previous randomized controlled trials on CPT for COVID-19.
• To propose early ambulatory administration of high-dose CPT to mitigate severe disease burden.

Main Methods:

• Review and analysis of existing observational studies and randomized controlled trials on convalescent plasma therapy for SARS-CoV-2.
• Comparison of trial outcomes based on the timing of CPT administration relative to symptom onset.
• Formulation of recommendations for future research and clinical practice.

Main Results:

• Evidence for CPT in SARS-CoV-2 is conflicting, influenced by study design and timing of intervention.
• Studies administering CPT later than 3 days post-diagnosis showed less favorable outcomes.
• A recent RCT supporting CPT administered therapy within 3 days of symptom onset.

Conclusions:

• Early administration of convalescent plasma (within 3 days of symptom onset) may be a promising strategy for treating SARS-CoV-2.
• Further rigorously designed RCTs are essential to definitively establish the efficacy of CPT for COVID-19.
• CPT could serve as a valuable early ambulatory treatment option, especially considering potential delays in global vaccine distribution.